Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  2. New drugs and therapeutic options help the immune system fight cancer
  3. Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
  4. The challenges of using stem cells in neurology
  5. Another BACE inhibitor fails in phase III trials

Latest Content

March’s top news stories

Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients with allergic conjunctivitis.

Stem Cells Sourced from Healthy and Diseased Donors

Caltag Medsystems specialises in procuring haematopoietic cells collected from healthy and diseased donors. Its suppliers are able to isolate and purify haematopoietic cells from a variety of tissues, including peripheral blood, mobilised peripheral blood, bone marrow and cord blood.

February’s top news stories

Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.

January’s top news stories

Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Customised R&D Services

AntalGenics offers the technology and knowledge required for the management of a wide variety of active ingredient formulation. Its research and development (R&D) capabilities provide high-quality design and development activities to meet the client's requirements.

Eligen® Technology Mechanism of Action

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top